Authors
Latest:
Efficient Gene Editing in Monogenic DiseasesAndré Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed the company’s expansion into gene therapies.
Latest:
Stephanie Cherqui, PhD, on Bringing Attention to Cystinosis and Gene TherapyThe associate professor from UC San Diego discussed promising efficacy and safety data from a phase 1/2 trial.
Latest:
Genovefa (Zenia) Papanicolaou, MD, on Managing Infectious Diseases in Patients Receiving Stem Cell Transplant or Cell TherapyThe infectious diseases specialist at Memorial Sloan Kettering Cancer Center discussed the session she chaired for the Infectious Diseases Track at Tandem’s 2024 Meeting.
Latest:
BASECAMP-1 Trial Identifies Patients With Solid Tumors to Assess Novel CAR T-Cell TherapyJ. Randolph Hecht, MD, discusses the challenges researchers have faced in the development of cellular therapy for patients with solid tumors, and details how A2B530 could potentially overcome some of these obstacles.
Latest:
Dilsher Dhoot, MD, on a Promising Start With Diabetic Retinopathy Gene Therapy RGX-314The adjunct clinical assistant professor, ophthalmology, Keck School of Medicine, University of Southern California discussed new data from the ALTITTUDE trial.
Latest:
Haydar Frangoul, MD, on Weighing Gene Therapy Against Haploidentical Transplant for Sickle Cell DiseaseThe medical director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed the pros and cons of potentially curative treatment options for SCD.
Latest:
Robert J. Hariri, MD, PhD, on the Unique Potential of Chimeric TherapyThe founder, chairman, and CEO of Celularity shared his view on the concept of “chimeric vigor” and the potential benefits arising from it in the cell therapy field.
Latest:
Weijia Fang, MD, and Guoqiang Ai, MD, on the Future of IMC001 in Gastric and Colorectal CancerFang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.
Latest:
The Power of Partnership in CMT Gene Therapy ResearchSusan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the origins of the CMTRF.
Latest:
Ami J. Shah, MD, on Reaching Normalized Hemoglobin With Gene-Edited Cell Therapy in PKDThe clinical professor of pediatrics at Stanford Medicine discussed positive interim findings from a phase 1 study of RP-L301.
Latest:
Selecting Cell Therapy Targets in CancerThe chief executive and medical officers of Cytovia Therapeutics discussed the company's therapeutic targets and cell therapy scaffold.
Latest:
Vlad Hogenhuis, MD, MBA, on Developing Controllable CAR Ts for Solid TumorsThe chief executive officer of Chimera Bioengineering discussed CBIO-007 and its planned IND submission for colorectal and triple negative breast cancer.
Latest:
Brett Kopelan, MA, on the Future Treatment of Epidermolysis Bullosa With Advanced TherapeuticsIn observance of Epidermolysis Bullosa Awareness Week, the executive director of debra of America discussed how a combination of advanced and topical approaches may represent the future of EB treatment.
Latest:
Dr. Anderson on Addressing Unmet Needs in Myeloma With Descartes-11Kenneth C. Anderson, MD, discusses potentially addressing unmet needs in patients with multiple myeloma through the use of the mRNA-based CAR T-cell therapy Descartes-11.
Latest:
Jason Fontenot, PhD, on Overcoming the Challenge of Delivery for Zinc Finger Epigenetic RepressorsThe chief scientific officer of Sangamo Therapeutics discussed the company’s AAV capsid evolution research.
Latest:
CARsgen Therapeutics’ CT041 Shows Promise in Advanced Gastric/Gastroesophageal Junction AdenocarcinomaThe chimeric antigen receptor-modified autologous T cells targeting CLDN18.2 had a manageable safety/tolerability profile and promising efficacy.
Latest:
Addressing Unmet Needs With Gene TherapyEric Crombez, PhD, senior vice president and chief medical officer of Ultragenyx Gene Therapy, discussed indications the company is targeting.
Latest:
Aimee Donald, MBChB, PhD, on Making Progress With Gene Therapy in Lysosomal Storage DiseasesThe pediatrician from Royal Manchester Children’s Hospital discussed how further research in Gaucher disease can benefit the field of rare lysosomal diseases as a whole.
Latest:
Assessing Efficacy of Fibroblast Cell Therapy in MS: Hamid Khoja, PhDThe chief scientific officer of FibroBiologics discussed efficacy findings from a phase 1/2 trial.
Latest:
Selecting Cell Therapy Targets in CancerThe chief executive and medical officers of Cytovia Therapeutics discussed the company's therapeutic targets and cell therapy scaffold.
Latest:
Donald Kohn, MD, on the Trajectory of Gene TherapyThe renowned professor from University of California Los Angeles reflected on receiving the Outstanding Achievement Award from the ASGCT.
Latest:
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024The McCaw Endowed Chair of Muscular Dystrophy at University of Washington discussed highlights from the meeting.
Latest:
Pamela Garzone, PhD, on Exploring Unknowns in CAR-T for Solid TumorsThe chief development officer of Anixa Biosciences discussed the company’s trial of a CAR-T in ovarian cancer that is looking at the effect of regional administration and lymphodepletion on efficacy.
Latest:
Alexandra Gomez-Arteaga, MD, on Expanding Eligibility for Cell Transplant With Cell TherapyThe Assistant Professor of Medicine at Weill Cornell Medical College discussed the changing cell transplant landscape.
Latest:
Challenges With Conducting Clinical Trials in Gaucher Disease: Neil Weinreb, MDThe chair of the International Collaborative Gaucher Group Registry discussed challenges in Gaucher research.
Latest:
CGTLive’s Weekly Rewind – April 8, 2022Review top news and interview highlights from the week ending April 8, 2022.
Latest:
Developing Controllable Tumor Infiltrating Lymphocyte TherapiesJan ter Meulen, MD, PhD, chief scientific officer, Obsidian Therapeutics, discussed the potential of the cytoDRIVE platform.
Latest:
Breanna DiAndreth, PhD, on Improving Selective Targeting of Tumor CellsThe scientist at A2 Biotherapeutics discussed the company’s dual-receptor Tmod technology.
Latest:
Looking Forward in Relapsed/Refractory Multiple Myeloma TreatmentsJames Hoffman, MD, leads a discussion about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.
Latest:
Jennifer Kwon, PhD, on Reducing LDL Cholesterol in NHPs With Epigenome EditingThe senior scientist at Tune Therapeutics discussed preclinical research presented at the ASGCT 2023 meeting.
